

Anti-H_OX40 hIgG2 Antibody(Ivuxolimab)

Product information

GM-23373AB-10	10 µg
GM-23373AB-100	100 µg
GM-23373AB-1000	1 mg

Antibody Information

Species Reactivity	Human
Clone	Ivuxolimab
Source/Isotype	Monoclonal human IgG2, κ
Application	Flow cytometry
Other Names	ACT35, CD134, IMD16, TXGP1L
Gene ID	P43489 (human)
Background	<p>OX40, also known as CD134 and Tumor necrosis factor receptor superfamily, member 4 (TNFRSF4), is a member of the TNFR-superfamily of receptors which is not constitutively expressed on resting naïve T cells, unlike CD28. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation; its ligand, OX40L, is also not expressed on resting antigen presenting cells, but is following their activation. Expression of OX40 is dependent on full activation of the T cell; without CD28, expression of OX40 is delayed and of fourfold lower levels. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response beyond the first few days and onwards to a memory response due to its ability to enhance survival. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions in vivo.</p>
Storage	Store at 2-8°C short term (1-2 weeks).Store at ≤ -20°C long term. Avoid repeated freeze-thaw.
Formulation	Phosphate-buffered solution, pH 7.2.
Endotoxin	< 1 EU/mg, determined by LAL gel clotting assay

Version:3.3

Data Examples

Flow cytometry

H_OX40 CHO-K1 Cell Line (Catalog # GM-C18986) was stained with Anti-H_OX40 hlgG2 Antibody (Ivuxolimab) or isotype control antibody, followed by anti-Human IgG FITC-conjugated Secondary Antibody.




Fig. FACS

Flow cytometry

H_OX40 Reporter Cell Line (Catalog # GM-C30855) was stained with A Anti-H_OX40 hlgG2 Antibody (Ivuxolimab) (Catalog # GM-23373AB) or isotype control antibody, followed by anti-Human IgG APC-conjugated Secondary Antibody.




Fig. FACS